GCA
AZN icon

Greenwood Capital Associates’s AstraZeneca AZN Stock Holding History

Greenwood Capital Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-51,110
Closed -$3.88M – 175
2018
Q4 		$3.88M Buy
+51,110
New +$3.99M 1.02% 42
2014
Q3 		– Sell
-31,482
Closed -$2.34M – 140
2014
Q2 		$2.34M Buy
+31,482
New +$2.28M 0.73% 62

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Greenwood Capital Associates's AZN Position: Q1 2019 in Review

Greenwood Capital Associates sold out of AstraZeneca (AZN) in Q1 2019, closing a stake of 51,110 shares — an estimated $3.88M sold.

Greenwood Capital Associates first reported a position in AZN in Q2 2014 and held it in 2 quarters. The position peaked at $3.88M in Q4 2018. 560 funds tracked by Wall St. Rank hold AZN as of Q1 2019.

  • Greenwood Capital Associates reported no remaining AstraZeneca position as of Q1 2019 after selling out during the quarter.
  • Greenwood Capital Associates sold 51,110 AstraZeneca shares in Q1 2019, an estimated $3.88M.
  • Greenwood Capital Associates first reported a position in AstraZeneca in Q2 2014 and held it in 2 quarters.
  • Greenwood Capital Associates's AstraZeneca position peaked at $3.88M in Q4 2018.
  • 560 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2019.

Based on Greenwood Capital Associates's 13F filing for Q1 2019, filed 3 May 2019.